223 related articles for article (PubMed ID: 16670912)
1. Cost-effectiveness of memantine in community-based Alzheimer's disease patients: An adaptation in Spain.
Antonanzas F; Rive B; Badenas JM; Gomez-Lus S; Guilhaume C
Eur J Health Econ; 2006 Jun; 7(2):137-44. PubMed ID: 16670912
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of memantine for moderate to severe Alzheimer's disease in Sweden.
Jönsson L
Am J Geriatr Pharmacother; 2005 Jun; 3(2):77-86. PubMed ID: 16129384
[TBL] [Abstract][Full Text] [Related]
3. Cost effectiveness of memantine in Alzheimer's disease: an analysis based on a probabilistic Markov model from a UK perspective.
Jones RW; McCrone P; Guilhaume C
Drugs Aging; 2004; 21(9):607-20. PubMed ID: 15260515
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of memantine in moderate-to-severe Alzheimer disease: the evidence to date.
Bullock R
Alzheimer Dis Assoc Disord; 2006; 20(1):23-9. PubMed ID: 16493232
[TBL] [Abstract][Full Text] [Related]
5. Memantine: new preparation. Poor evaluation and uncertain benefit in Alzheimer's disease.
Prescrire Int; 2003 Dec; 12(68):203-5. PubMed ID: 14986682
[TBL] [Abstract][Full Text] [Related]
6. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway.
Rive B; Aarsland D; Grishchenko M; Cochran J; Lamure M; Toumi M
Int J Geriatr Psychiatry; 2012 Jun; 27(6):573-82. PubMed ID: 21834130
[TBL] [Abstract][Full Text] [Related]
8. Memantine for treatment of moderate to severe Alzheimer's disease.
Perras C
Issues Emerg Health Technol; 2005 Mar; (64):1-4. PubMed ID: 15762015
[TBL] [Abstract][Full Text] [Related]
9. Activities of daily living in moderate-to-severe Alzheimer disease: an analysis of the treatment effects of memantine in patients receiving stable donepezil treatment.
Feldman HH; Schmitt FA; Olin JT;
Alzheimer Dis Assoc Disord; 2006; 20(4):263-8. PubMed ID: 17132971
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease.
López-Bastida J; Hart W; García-Pérez L; Linertová R
J Alzheimers Dis; 2009; 16(2):399-407. PubMed ID: 19221429
[TBL] [Abstract][Full Text] [Related]
11. Improvement in behavioural symptoms in patients with moderate to severe Alzheimer's disease by memantine: a pooled data analysis.
Gauthier S; Loft H; Cummings J
Int J Geriatr Psychiatry; 2008 May; 23(5):537-45. PubMed ID: 18058838
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
13. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
Plosker GL; Lyseng-Williamson KA
Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
[TBL] [Abstract][Full Text] [Related]
14. [Memantine in the pharmacologic treatment of moderately severe to severe Alzheimer's disease in Spain (MEMORY study)].
Agüera-Ortiz LF;
Rev Neurol; 2010 Nov; 51(9):525-34. PubMed ID: 20979032
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of memantine in moderately severe to severe Alzheimer's disease : a markov model in Finland.
François C; Sintonen H; Sulkava R; Rive B
Clin Drug Investig; 2004; 24(7):373-84. PubMed ID: 17516724
[TBL] [Abstract][Full Text] [Related]
16. Memantine treatment of cognitive symptoms in mild to moderate Alzheimer disease: secondary analyses from a placebo-controlled randomized trial.
Pomara N; Ott BR; Peskind E; Resnick EM
Alzheimer Dis Assoc Disord; 2007; 21(1):60-4. PubMed ID: 17334274
[TBL] [Abstract][Full Text] [Related]
17. Analysis of the effect of memantine in reducing the worsening of clinical symptoms in patients with moderate to severe Alzheimer's disease.
Wilkinson D; Andersen HF
Dement Geriatr Cogn Disord; 2007; 24(2):138-45. PubMed ID: 17622761
[TBL] [Abstract][Full Text] [Related]
18. The clinical and cost-effectiveness of donepezil, rivastigmine, galantamine and memantine for Alzheimer's disease.
Loveman E; Green C; Kirby J; Takeda A; Picot J; Payne E; Clegg A
Health Technol Assess; 2006 Jan; 10(1):iii-iv, ix-xi, 1-160. PubMed ID: 16409879
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of memantine in Alzheimer's disease in the UK.
Rive B; Grishchenko M; Guilhaume-Goulant C; Katona C; Livingston G; Lamure M; Toumi M; François C
J Med Econ; 2010; 13(2):371-80. PubMed ID: 20504112
[TBL] [Abstract][Full Text] [Related]
20. Memantine enhances autonomy in moderate to severe Alzheimer's disease.
Rive B; Vercelletto M; Damier FD; Cochran J; François C
Int J Geriatr Psychiatry; 2004 May; 19(5):458-64. PubMed ID: 15156547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]